Bionano Genomics Expands Its Diagnostic Testing Menu with Launch of Lineagen’s EpiPanelDx PLUS Gene Panel Test that Identifies Genetic Conditions Related to Epilepsy
September 14, 2020 08:00 ET | Source: Bionano Genomics
EpiPanelDx PLUS adds to Lineagen’s expanding menu of diagnostic tests for children with developmental disorders and provides an offering designed specifically for patients that have experienced seizures or other epilepsy-related symptoms
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the release of EpiPanelDx PLUS™ by its diagnostics services business, Lineagen. The new laboratory developed test (LDT) and associated clinical support bolsters Lineagen’s diagnostic services for physicians providing care for pediatric patients with neurodevelopmental disorders (NDDs). EpiPanelDx PLUS is based on a proprietary panel of 223 genes associated with epilepsy-related conditions, more genes than typically found on epilepsy panels available from other service providers and customized for Lineagen’s core market of neurodevelopmental disorders.